Substituted pyridazinone compound
The present invention relates to a pharmaceutical composition of a substituted pyridazinone compound and use thereof. The substituted pyridazinone compound is a compound as represented by formula (I), or a pharmaceutically acceptable salt, a prodrug, a hydrate or solvent compound, a crystalline form, and a stereoisomer or isotopic variant thereof. The compound is a THR-beta agonist which can be used for treating and/or preventing diseases regulated by thyroid hormone analogues.
1. A compound of formula (I), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, crystal form, stereoisomer or isotopic variant thereof:
wherein,
R 1 and R 2 are hydrogen;
R 3 and R 4 are independently selected from hydrogen and deuterium;
X 1 and X 2 are independently selected from CH 3 , CD 3 , CHD 2 and CH 2 D;
with the proviso that if X 1 and X 2 are both CH 3 , then at least one of R 3 and R 4 is deuterium.
2. The compound, pharmaceutically acceptable salt, prodrug, hydrate, solvate, crystal form, stereoisomer or isotopic variant thereof according to claim 1 , wherein R 3 and R 4 are hydrogen.
3. The compound, pharmaceutically acceptable salt, prodrug, hydrate, solvate, crystal form, stereoisomer or isotopic variant thereof according to claim 1 , wherein X 1 is CD 3 .
4. The compound, pharmaceutically acceptable salt, prodrug, hydrate, solvate, crystal form, stereoisomer or isotopic variant thereof according to claim 1 , wherein X 2 is CD 3 .
5. The compound, or the pharmaceutically acceptable salt, prodrug, hydrate, solvate, crystal form, stereoisomer or isotopic variant thereof according to claim 1 , wherein the compound is selected from the following compounds:
6. A pharmaceutical composition, comprising pharmaceutically acceptable excipient(s) and the compound, or the pharmaceutically acceptable salt, prodrug, hydrate, solvate, crystal form, stereoisomer or isotopic variant thereof according to claim 1 .